Why the study?
Does a continuous-flow left ventricular assist device improve survival free from stroke and device failure in patients with advanced heart failure compared to a pulsatile device?
Does a continuous-flow left ventricular assist device improve survival free from stroke and device failure in patients with advanced heart failure compared to a pulsatile device?
Continuous-flow LVADs provide superior 2-year survival free from stroke and device failure compared to pulsatile devices in patients with advanced heart failure.
Continuous-flow LVADs merit preference over pulsatile devices in advanced HF; confirms randomized superiority for 2-year outcomes.
Treatment with a continuous-flow left ventricular assist device in patients with advanced heart failure significantly improved the probability of survival free from stroke and device failure at 2 years as compared with a pulsatile device. Both devices significantly improved the quality of life and functional capacity. (ClinicalTrials.gov number, NCT00121485.)
No takes yet. Share an insight, caveat, or question.
Slaughter et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: